The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

CONCLUSION: Among patients with stage IIIA endometrial cancer, metastasis to adnexae or serosa does not appear to confer worse prognosis than positive cytology alone. Positive cytology is an ...

A coroner found there were "missed opportunities" to treat a 38-year-old woman with cancer. Carla Smith, 38, who died on 7 ...

Approximately 25% of women develop recurrence or distant metastasis. Laparoscopic surgery for stage I endometrial cancer produces better short-term outcomes and fewer severe postoperative ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

But when left untreated, endometrial cancer may start to spread through the wall of the uterus and into the pelvis, causing ...

In most cases, we only recommend other therapies — such as chemotherapy, hormone therapy, or radiation therapy — if the cancer has spread into the deep uterine muscle layer or beyond. We also offer ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...

The results of a multisite clinical trial overseen by University of Colorado Cancer Center member Bradley Corr, MD, could offer new hope to patients with metastatic and recurrent uterine cancer ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first ...